Free Myeloperoxidase Levels Show Promise for Predicting Risk of Cardiovascular, All-Cause Mortality
August 12th 2023New research suggests that measuring the inflammatory marker myeloperoxidase (MPO) may be an effective strategy for the prediction of patients' risk of mortality in a myriad of cardiac—and potentially non-cardiac—diseases.
Read More
Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines
August 12th 2023Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
Axi-Cel Extends Survival vs Standard of Care for R/R LBCL
August 11th 2023An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Read More
Cost Burden of Hospital-Onset CDI Higher Than Community-Associated CDI
August 11th 2023Researchers found that costs were highest for those with hospital-onset clostridioides difficile infection (CDI), lower for those with community onset-health care facility association CDI, and lowest for those with community-associated CDI.
Read More
Active AD Prevalent in 2.4% of the UK Adult Population
August 10th 2023Researchers found that 2.4% of the adult UK population had active atopic dermatitis (AD) between 2015 and 2019, the majority of which were mild cases of AD, as only 7.5% to 8.3% of the population had moderate to severe AD.
Read More
SPRINT Data Link Reduced Mortality, Total Physical Activity in High-Risk Hypertension
August 10th 2023Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).
Read More
Novo Nordisk continues to limit starter doses of popular weight-loss drug Wegovy in the US; veterans and survivors received an error message when submitting PACT Act claims shortly before the deadline; insurance companies are failing to inform patients of their eligibility for free preventative services.
Read More